COVID-19 Boosts Sanofi's Ageing Lovenox Franchise, But Holds Back Travel Vaccine Sales
Vaccines Near Late-Stage Studies
The COVID-19 pandemic led to a marked increase in sales of Sanofi’s LMW heparin, Lovenox, in the first quarter of 2021. The big pharma is also nearing late-stage clinical studies with two COVID-19 vaccine candidates.
